Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for ulcerative ...

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

The Paul-Ehrlich-Institute (PEI) in Germany has granted approval to continue subject enrolment in cohort 5 of Oncolytics' GOBLET trial ...

JP Morgan attendees were told of Jazz Pharmaceuticals' plans to expand indications for two oncology drugs: zanidatamab and ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting gynaecologic and testicular cancers.

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of PH284 for the treatment of cancer cachexia.